中国药师2024,Vol.28Issue(9) :144-154.DOI:10.12173/j.issn.2097-4922.202404140

中药治疗幽门螺旋杆菌感染的研究进展

Research progress in the treatment of Helicobacter pylori infection with traditional Chinese medicine

刘子熙 侯林
中国药师2024,Vol.28Issue(9) :144-154.DOI:10.12173/j.issn.2097-4922.202404140

中药治疗幽门螺旋杆菌感染的研究进展

Research progress in the treatment of Helicobacter pylori infection with traditional Chinese medicine

刘子熙 1侯林1
扫码查看

作者信息

  • 1. 山东中医药大学青岛中医药科学院(山东青岛 266109)
  • 折叠

摘要

幽门螺旋杆菌(Hp)是一种革兰氏阴性菌,主要定植于胃和十二指肠,可引起胃炎、消化性溃疡和胃癌等疾病.Hp相关的胃癌是人类最常见的恶性肿瘤之一,是全球癌症相关死亡的第四大原因,严重威胁着人类的健康,因此Hp的根除显得尤为重要.但随着抗生素的滥用,该菌的耐药性也大大提升,以往的研究方案逐渐显露出弊端,而中药治疗具有复发率低、不良反应少、不易产生耐药性等独特优势.充分发挥中药优势,不断研究新的治疗方案对Hp的根除具有重大意义.该文主要对Hp的病理机制和治疗进展、中药治疗进行综述.

Abstract

Helicobacter pylori(Hp)is a gram-negative bacterium which colonizes the stomach and duodenum,and can cause diseases such as gastritis,peptic ulcers and stomach cancer.Gastric cancer associated with Hp is one of the most common human malignancies,the fourth leading cause of cancer-related death worldwide,and a serious threat to human health,so the eradication of Hp is particularly important.However,with the abuse of antibiotics,the drug resistance of the bacteria has also been greatly improved,and the previous research schemes have gradually revealed drawbacks,while Chinese medicine treatment has unique advantages such as low recurrence rate,few side effects,and not easy to produce drug resistance.It is of great significance to make full use of the advantages of traditional Chinese medicine and continuously study new treatment plans for the eradication of Hp.This article mainly reviews the pathological mechanism,treatment progress and traditional Chinese medicine treatment of Hp.

关键词

幽门螺旋杆菌/病理机制/治疗进展/中药治疗//十二指肠/黄连/黄芩/大黄/地榆/苍术/栀子

Key words

Helicobacter pylori/Pathological pathological mechanism/Treatment progress/Chinese medicine treatment/Stomach/Duodemum/Coptidis rhizoma/Scutellariae radix/Rhei radix et rhizoma/Sanguisorbae radix/Atractylodis rhizoma/Gardeniae fructus

引用本文复制引用

出版年

2024
中国药师
国家药品监督管理局高级研修学院,武汉医药(集团)股份有限公司

中国药师

CSTPCD
影响因子:0.944
ISSN:1008-049X
段落导航相关论文